Predictors of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Population-Based Study in Northeastern Iran
Gastroenterology and Hepatology from Bed to Bench,
30 December 2021
Aim: The current study was designed to determine the predictive risk factors of metabolic
dysfunction-associated fatty liver disease (MAFLD) among Iranian population.
Background: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease has renamed
to the new terminology of MAFLD. While there is no approved treatment for fatty liver diseases,
identifying the risk factors of MAFLD is more important than other non-communicable diseases.
Methods: This nested case-control study was performed based on the Persian Sabzevar Cohort
Study (PSCS) consisting of 4,242 participants in northeastern Iran with an age range of 35 to 70
years. We recruited 968 MAFLD cases and 964 age and sex- matched controls. We collected
data including demographic, lifestyle, anthropometric, biochemical, dietary habits, and sleep
Results: The mean age of the participants was 49.2 ± 8.8 years, and 39.9% of them were male.
The prevalence of MAFLD in the studied population was 22.8%. Increase in body mass index
(BMI) (OR [odds ratios] 5.51, 95% CI [confidence interval] 2.73 – 11.10), waist circumference
(WC) (OR 1.85, 95% CI 1.44 – 2.38), triglyceride (TG) (OR 1.10, 95% CI 1.06 – 1.15), total
cholesterol (TC) (OR 1.02, 95% CI 1.003 – 1.04), and AST (OR 1.10, 95% CI 1.05 – 1.16) were
statistically significantly associated with higher risk of MAFLD (P <0.05 for all). Furthermore,
the risk of having MAFLD was 43% higher in subjects who sleep less than five compared to
those with more than 7-hour sleep/day (OR 1.43; 95% CI 1.07 – 1.92, P = 0.01)
Conclusion: In our study, BMI, WC, plasma levels of TG, total cholesterol, and AST are the
best predictors of MAFLD. Sleeping ≤ 5 relative to more than 7 hours/day increases the MAFLD
- Metabolic associated fatty liver disease
- Non-alcoholic fatty liver disease
- Risk factors
hepatology 2013; 10: 686-90.
2. Byrne CD, Targher G. NAFLD: a multisystem disease. Journal of hepatology 2015; 62:
3. Povsic M, Wong OY, Perry R, Bottomley J. A structured literature review of the
epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Advances in
therapy 2019: 1-21.
4. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease:
clinical associations, pathophysiological mechanisms and pharmacological implications.
Gut 2020; 69: 1691-705.
5. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al.
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of
incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and
meta-analysis. Journal of gastroenterology and hepatology 2016; 31: 936-44.
6. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. Journal of
hepatology 2020; 72: 785-801.
7. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and
dyslipidemia: An update. Metabolism: clinical and experimental 2016; 65: 1109-23.
8. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World journal
of gastroenterology 2014; 20: 8407-15.
9. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver
disease: a precursor of the metabolic syndrome. Digestive and liver disease : official
journal of the Italian Society of Gastroenterology and the Italian Association for the
Study of the Liver 2015; 47: 181-90.
10. Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al.
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of
cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;
11. Qorbani M, Kelishadi R, Taheri E, Motlagh ME, Arzaghi SM, Ardalan G, et al.
Association between psychosocial distress with cardio metabolic risk factors and liver
enzymes in a nationally-representative sample of Iranian children and adolescents: the
CASPIAN-III study. Journal of Diabetes & Metabolic Disorders 2014; 13: 1-8.
12. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of
nonalcoholic fatty liver disease demonstrates an exponential increase in burden of
disease. Hepatology 2018; 67: 123-33.
13. Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and
inflammation in nonalcoholic fatty liver disease. Lipids in health and disease 2017; 16: 1-
14. Johnston MP, Patel J, Byrne CD. Causes of mortality in non-alcoholic fatty liver disease
(nafld) and alcohol related fatty liver disease (afld). Current pharmaceutical design 2020;
15. Zheng KI, Fan J-G, Shi J-P, Wong VW-S, Eslam M, George J, et al. From NAFLD to
MAFLD: a ―redefining‖ moment for fatty liver disease. Chinese medical journal 2020;
Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al.
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver
disease. Gastroenterology 2020; 158: 1999-2014. e1.
17. Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of
lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis. Journal of
Gastroenterology and Hepatology 2020; 35: 2041-50.
18. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global
epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review
and meta-analysis. Journal of hepatology 2019; 71: 793-801.
19. Licher S, Heshmatollah A, van der Willik KD, Stricker BHC, Ruiter R, de Roos EW, et
al. Lifetime risk and multimorbidity of non-communicable diseases and disease-free life
expectancy in the general population: a population-based cohort study. PLoS medicine
2019; 16: e1002741.
20. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al.
Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study):
rationale, objectives, and design. American journal of epidemiology 2018; 187: 647-55.
21. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The
Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general
population. BMC gastroenterology 2006; 6: 1-7.
22. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to use
principal components analysis. Health policy and planning 2006; 21: 459-68.
23. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of
metabolic dysfunction-associated fatty liver disease in overweight or obese adults.
Clinical Gastroenterology and Hepatology 2021.
24. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M,
et al. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. Int
J Organ Transplant Med 2016; 7: 149-60.
25. Salehisahlabadi A, Sadat S, Lotfi A, Mohseni M, Jadidi H. Prevalence of Non-Alcoholic
Fatty Liver Disease in Iran: A Population Based Study.
26. Zarean E, Goujani R, Rahimian G, Ahamdi A. Prevalence and risk factors of non-
alcoholic fatty liver disease in southwest Iran: a population-based case-control study. Clin
Exp Hepatol 2019; 5: 224-31.
27. Niriella MA, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva
AP, et al. Outcomes of NAFLD and MAFLD: Results from a community-based,
prospective cohort study. PloS one 2021; 16: e0245762.
28. Fan J-G, Kim S-U, Wong VW-S. New trends on obesity and NAFLD in Asia. Journal of
hepatology 2017; 67: 862-73.
29. Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance:
new insights and potential new treatments. Nutrients 2017; 9: 387.
30. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Nonalcoholic
Steatohepatitis Clinical Research Network Association between diabetes, family history
of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56:
31. Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al.
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
The Journal of clinical investigation 2020; 130: 1453-60.
linking NAFLD and insulin resistance. Endocrine Reviews 2019; 40: 1367-93.
33. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin
resistance. Nature Reviews Endocrinology 2017; 13: 509-20.
34. Adibi A, Maleki S, Adibi P, Etminani R, Hovsepian S. Prevalence of nonalcoholic fatty
liver disease and its related metabolic risk factors in Isfahan, Iran. Advanced biomedical
research 2017; 6.
35. Tang Z, Pham M, Hao Y, Wang F, Patel D, Jean-Baptiste L, et al. Sex, age, and BMI
modulate the association of physical examinations and blood biochemistry parameters
and NAFLD: a retrospective study on 1994 cases observed at Shuguang Hospital, China.
BioMed research international 2019; 2019.
36. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors
and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A
systematic review and meta-analysis of population-based observational studies. PLoS
Med 2020; 17: e1003100.
37. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Short sleep
duration is a risk of incident nonalcoholic fatty liver disease: a population-based
longitudinal study. J Gastrointestin Liver Dis 2019; 28: 73-81.
38. Kim JH, Jung DH, Kwon YJ, Lee JI, Shim JY. The impact of the sleep duration on
NAFLD score in Korean middle-aged adults: a community-based cohort study. Sleep
Med 2019; 57: 144-50.
- Abstract Viewed: 0 times